Recognition highlights company's people-first culture and contribution to healthcare access, community development and nation-building
The product will be offered as a pre-filled, multi-dose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—enabling flexible once-weekly dosing
Both the companies are evaluating pharmaceutical-grade ingredients with established safety profiles as potential excipients for biologic formulations
Under the licensing agreement, AstraZeneca will pay $600 million upfront, with up to $900 million in additional payments tied to development, regulatory and commercial milestones
A key highlight will be the latest findings from the global Phase-3 Masupirdine study, including demographic and clinical characteristics of enrolled patients
As studies confirm comparable results to Eylea in eye disease treatment
The approval advances company’s goal of launching 20 biosimilar products in the U.S. by 2030
This marks a major step forward in the company’s efforts to develop advanced cell therapies for hard-to-treat cancers
Company consolidates 100% stake in subsidiary as it sharpens focus on biologics and biosimilars
Government-backed project aims to advance personalised chemotherapy screening using patient-derived tumour organoids
The proposed subsidiary will evaluate opportunities through joint ventures and strategic investments in innovative therapeutic areas
The buyer, Immunoscript Life Science Private Limited, is a newly incorporated company promoted by Dr. Sanjay Singh, who previously served as a Director of Gennova Biopharmaceuticals
Team NIB at XSeed Labs to develop human in vitro platform for accelerating discovery and validation of innovative intraocular biologics
The collaboration will test Apertura’s proprietary TfR1 CapX AAV capsid, a next-generation delivery technology designed to bind transferrin receptor 1 (TfR1)
The company has announced that its MFG8 drug substance manufacturing facility in Hebei successfully passed a US FDA Pre-License Inspection (PLI)
The acceptance of DMF #32973 strengthens Porton Advanced’s position in the fast-growing exosome therapeutics sector
The partnership highlights both companies’ commitment to increasing availability of high-quality biologic medicines while supporting more sustainable healthcare systems globally
The collaboration is expected to provide researchers and students with greater exposure to real-world drug development challenges
The incidents were reported to WHO by national regulatory authorities in the Maldives and Mexico in May and June 2026
The partnership will bring Arima’s genomic architecture tools to researchers studying epigenetics, gene regulation, human health and disease, as well as reference-quality genome assembly and haplotype phasing
Subscribe To Our Newsletter & Stay Updated
